{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:28:01Z","timestamp":1787167681582,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T00:00:00Z","timestamp":1269388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11926-010-0093-2","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T03:00:42Z","timestamp":1269313242000},"page":"130-134","source":"Crossref","is-referenced-by-count":23,"title":["New Agents for the Treatment of Gout and Hyperuricemia: Febuxostat, Puricase, and Beyond"],"prefix":"10.1007","volume":"12","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,24]]},"reference":[{"key":"93_CR1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.7326\/0003-4819-8-12-1673","volume":"8","author":"PS Hench","year":"1935","unstructured":"Hench PS, Bauer W, Fletcher AA, et al.: Present status of the problem of \u201crheumatism\u201d: review of recent American and English literature on \u201crheumatism\u201d and arthritis (part 3). Ann Intern Med 1935, 8:1673\u20131697.","journal-title":"Ann Intern Med"},{"key":"93_CR2","first-page":"536","volume-title":"Basic and Clinical Pharmacology","author":"BG Katzung","year":"1995","unstructured":"Katzung BG: Basic and Clinical Pharmacology. Edited by Katzung BG. Norwalk, CT: Appleton and Lange; 1995:536\u2013559."},{"key":"93_CR3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237\u2013241.","journal-title":"Nature"},{"key":"93_CR4","first-page":"S1108","volume":"59","author":"B Terkeltaub","year":"2009","unstructured":"\u2022 Terkeltaub B, Furst DE, Bennett K, et al.: Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Arthritis Rheum 2009, 59:S1108. This study highlights needed information about colchicine dosing in acute gout.","journal-title":"Arthritis Rheum"},{"key":"93_CR5","unstructured":"Colcrys.com: Highlights of prescribing information. Available at http:\/\/www.colcrys.com\/assets\/pdf\/COLCRYS_Full_Prescribing_Information.pdf . Accessed January 2010."},{"key":"93_CR6","unstructured":"US Food and Drug Administration: Highlights of prescribing information: Colocrys. Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022351lbl.pdf . Accessed January 2010."},{"key":"93_CR7","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","volume":"138","author":"FS Giovine Di","year":"1987","unstructured":"Di Giovine FS, Malawista SE, Nuki G, Duff GW: Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987, 138:3213\u20133218.","journal-title":"J Immunol"},{"key":"93_CR8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","volume":"8","author":"RN Cronstein","year":"2006","unstructured":"Cronstein RN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther 2006, 8:S3.","journal-title":"Arthritis Res Ther"},{"key":"93_CR9","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"12","author":"A So","year":"2007","unstructured":"\u2022\u2022 So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007,12:R28. This important pilot study demonstrated that IL-1 blockade is helpful in the treatment of acute gout.","journal-title":"Arthritis Res Ther"},{"key":"93_CR10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","volume":"68","author":"R Terkeltaub","year":"2009","unstructured":"Terkeltaub R, Sundy JS, Schumacher HR, et al.: The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 2009, 68:1613\u20131617.","journal-title":"Ann Rheum Dis"},{"key":"93_CR11","unstructured":"\u2022\u2022 So A, De Meulemeester M, Shamim T, et al.: Canakinumab (ACZ885) vs. triamcinolone actonide for treatment of acute gout in patients refractory or contraindicated to NSAIDs and\/or colchicine. Late breaking abstract. Arthritis Rheum 2009, 60:LB4 p3660-1. This important large study in acute gout demonstrated that IL-1 blockade is helpful, especially compared with triamcinolone in the treatment of acute gout."},{"key":"93_CR12","first-page":"S1096","volume":"59","author":"HR Schumacher","year":"2009","unstructured":"\u2022\u2022 Schumacher HR, Sundy JS, Terkeltaub R, et al.: Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy. Arthritis Rheum 2009, 59:S1096. This important study demonstrates the use of IL-1 blockade in gout prophylaxis.","journal-title":"Arthritis Rheum"},{"key":"93_CR13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","volume":"23","author":"MA Becker","year":"2004","unstructured":"Becker MA, Kisicki J, Khosravan R, et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23:1111\u20131116.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"93_CR14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270005282634","volume":"46","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Mayer MD, et al.: The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006, 46:88\u2013102.","journal-title":"J Clin Pharmacol"},{"key":"93_CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, et al.: PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate kidney disease (chronic kidney disease (CKD) stages 2 and 3). Nucleosides Nucleotides Nucleic Acids 2004, 23:1117\u20131118. This noteworthy study demonstrated the pharmacokinetics, pharmacodynamics, and safety of febuxostat in patients with CKD 2 and 3.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"93_CR16","first-page":"4029","volume":"58","author":"MA Becker","year":"2008","unstructured":"Becker MA, Schumacher HR Jr, Espinosa L, et al.: A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout. Arthritis Rheum 2008, 58:4029\u20134029.","journal-title":"Arthritis Rheum"},{"key":"93_CR17","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450\u20132461.","journal-title":"N Engl J Med"},{"key":"93_CR18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, et al.: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009, 48:188\u2013194.","journal-title":"Rheumatology"},{"key":"93_CR19","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1096\/fasebj.2.15.3192041","volume":"2","author":"A Varela-Echavarria","year":"1988","unstructured":"Varela-Echavarria A, Montes de Oca-Luna R, Barrera-Saldana HA: Uricase protein sequences: conserved during vertebrate evolution but absent in humans. The FASEB Journal 1988, 2:3092\u20133096.","journal-title":"The FASEB Journal"},{"key":"93_CR20","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"SC Goldman","year":"2001","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998\u20133003.","journal-title":"Blood"},{"key":"93_CR21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","volume":"25","author":"JD Moolenburgh","year":"2006","unstructured":"Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749\u2013752.","journal-title":"Clin Rheumatol"},{"key":"93_CR22","first-page":"2093","volume":"34","author":"P Richette","year":"2007","unstructured":"Richette P, Briere C, Hoenen-Clavert V, et al.: Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34:2093\u20132098.","journal-title":"J Rheumatol"},{"key":"93_CR23","doi-asserted-by":"crossref","first-page":"S635","DOI":"10.1002\/art.23810","volume":"58","author":"JS Sundy","year":"2008","unstructured":"\u2022\u2022 Sundy JS, Baraf HS, Becker MA, et al.: Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): phase 3 results from GOUT1 and GOUT2. Arthritis Rheum 2008, 58:S635. This noteworthy study reviewed the use of pegloticase as urate-lowering therapy in patients with chronic severe gout.","journal-title":"Arthritis Rheum"},{"key":"93_CR24","first-page":"S1104","volume":"59","author":"D Wright","year":"2009","unstructured":"Wright D, Sundy JS, Rosario-Jansen T: Routine serum uric acid (SUA) monitoring predicts antibody-mediated loss of response and infusion reaction risk during pegloticase therapy. Arthritis Rheum 2009, 59:S1104.","journal-title":"Arthritis Rheum"},{"key":"93_CR25","first-page":"S1111","volume":"59","author":"AN Maroli","year":"2009","unstructured":"Maroli AN, Waltrip R, Alton M, et al.: First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout. Arthritis Rheum 2009, 59:S1111.","journal-title":"Arthritis Rheum"},{"key":"93_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11926-004-0075-3","volume":"6","author":"JS Bomalaski","year":"2004","unstructured":"Bomalaski JS, Clark MA: Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheum Rep 2004, 6:240\u2013247.","journal-title":"Curr Rheum Rep"},{"key":"93_CR27","unstructured":"Ardea Biosciences: Development pipeline: gout. Available at http:\/\/www.ardeabio.com\/gout.html . Accessed January 2010."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0093-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0093-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0093-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:46:51Z","timestamp":1685494011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0093-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,24]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["93"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0093-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,24]]}}}